GoodRx (NASDAQ:GDRX) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of GoodRx (NASDAQ:GDRX) from a sell rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “GoodRx Holdings Inc. provides consumer-focused digital healthcare platform. GoodRx Holdings Inc. is based in Santa Monica, California. “

A number of other equities analysts also recently commented on the stock. Barclays lifted their price objective on shares of GoodRx from $45.00 to $47.00 and gave the stock an overweight rating in a report on Thursday, November 11th. SVB Leerink decreased their price objective on shares of GoodRx from $56.00 to $49.00 and set an outperform rating for the company in a report on Thursday, November 11th. Credit Suisse Group lifted their price objective on shares of GoodRx from $45.00 to $52.00 and gave the stock an outperform rating in a report on Tuesday, September 14th. Robert W. Baird decreased their price objective on shares of GoodRx from $40.00 to $34.00 in a report on Wednesday, January 5th. Finally, Stephens assumed coverage on shares of GoodRx in a report on Tuesday, December 21st. They issued an overweight rating and a $45.00 price objective for the company. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of Buy and a consensus price target of $47.07.

GDRX stock opened at $26.85 on Tuesday. GoodRx has a twelve month low of $25.07 and a twelve month high of $59.67. The company has a debt-to-equity ratio of 0.78, a current ratio of 14.47 and a quick ratio of 14.47. The firm has a 50 day simple moving average of $35.98 and a 200-day simple moving average of $37.49.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, November 10th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.08. GoodRx had a negative net margin of 41.36% and a negative return on equity of 31.61%. The business had revenue of $195.10 million during the quarter, compared to the consensus estimate of $196.08 million. During the same quarter last year, the company earned ($0.25) earnings per share. On average, equities analysts anticipate that GoodRx will post 0.05 earnings per share for the current fiscal year.

In related news, insider Bansi Nagji sold 16,300 shares of GoodRx stock in a transaction dated Wednesday, October 20th. The shares were sold at an average price of $45.00, for a total transaction of $733,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Abdiel Capital Management, Llc sold 99,135 shares of GoodRx stock in a transaction dated Wednesday, December 15th. The shares were sold at an average price of $35.97, for a total transaction of $3,565,885.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,393,259 shares of company stock valued at $53,631,621. Corporate insiders own 1.43% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Spire Wealth Management raised its stake in shares of GoodRx by 50.0% during the fourth quarter. Spire Wealth Management now owns 1,500 shares of the company’s stock valued at $49,000 after purchasing an additional 500 shares in the last quarter. IFP Advisors Inc raised its position in GoodRx by 301.0% in the fourth quarter. IFP Advisors Inc now owns 1,163 shares of the company’s stock worth $41,000 after acquiring an additional 873 shares in the last quarter. Moors & Cabot Inc. bought a new stake in GoodRx in the third quarter worth about $1,117,000. Kingsview Wealth Management LLC bought a new stake in GoodRx in the third quarter worth about $230,000. Finally, Bank of New York Mellon Corp raised its position in GoodRx by 14.4% in the third quarter. Bank of New York Mellon Corp now owns 39,596 shares of the company’s stock worth $1,624,000 after acquiring an additional 4,999 shares in the last quarter. Institutional investors and hedge funds own 52.26% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

See Also: S&P/TSX Index

Get a free copy of the Zacks research report on GoodRx (GDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.